Andrx Picks Up Lovenox Generic Marketing Rights From Amphastar

Under the $10 mil. deal, Andrx obtains rights to market two strengths of the injectable antithrombotic in the U.S. retail pharmacy market. Amphastar will be responsible for ongoing enoxaparin patent litigation with Sanofi-Aventis. The 30-month stay on Amphastar’s ANDA runs through February 2006.